Carmell Corp
NASDAQ:CTCX
Net Margin
Carmell Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
C
|
Carmell Corp
NASDAQ:CTCX
|
5.9m USD |
-77 973%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.8B USD |
6%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
158.4B USD |
19%
|
|
| US |
U
|
US BioTec Inc
OTC:USBC
|
156.3B USD | N/A | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
142.9B USD |
22%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.6B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
104.9B AUD |
19%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.4B USD |
31%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
59.9B USD |
-13%
|
Carmell Corp
Glance View
Carmell Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 10 full-time employees. The company went IPO on 2021-07-29. Carmell Corporation, formerly Carmell Therapeutics Corporation, is a regenerative medicine platform company. The firm is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. Its lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing its core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Carmell Corp's most recent financial statements, the company has Net Margin of -77 972.9%.
You don't have any saved screeners yet